Top Stories
BAKERHOSTETLER ADDS INTERNATIONAL LAWYER TO GROWING ANDA PRACTICE
Published by Gbaf News
Posted on September 16, 2016
6 min readLast updated: January 22, 2026
Global Banking & Finance Review®
Company
Published by Gbaf News
Posted on September 16, 2016
6 min readLast updated: January 22, 2026
Biologics and pharmaceutical litigator Irene Hudson strengthens IP Group
BakerHostetler today announced that biologics and pharmaceutical litigator Irene Hudson has joined the Intellectual Property Group and the Biotechnology, Chemical and Pharmaceutical team, resident in the New York office as partner. Hudson comes to BakerHostetler from Fish & Richardson.
Hudson will concentrate her practice on representing domestic and international biologics, pharmaceutical and medical device companies on complex patent infringement litigation, with a particular focus on Hatch-Waxman-based litigation. With a background in pharmacy, Hudson draws on her knowledge of the Food and Drug Administration’s (FDA’s) regulations and statutes concerning New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), Biologics License Applications (BLAs), new drug product exclusivity, and the Hatch-Waxman and Biologics Price Competition and Innovation Act to devise strategies to guide clients through exclusivity rights and challenges involving litigation, arbitration, or mediation.
As part of BakerHostetler’s ongoing strategic expansion in this practice area, Hudson joins other recent additions, Partner Ben Hsing and Counsel Wanda French-Brown. With one of the nation’s largest IP practices, the firm has more than 170 dedicated IP lawyers, with over 100 lawyers and patent agents registered to practice before the U.S. Patent and Trademark Office. “Over the past year, BakerHostetler has focused on building a comprehensive ANDA practice to service our growing roster of clients in the pharmaceutical industry,” said John Weber, Chair of the Intellectual Property Group. “Irene’s extensive experience, particularly working with pharmaceutical and medical device companies, continues to enhance the firm’s specialized skills in this practice area.”
Representing Fortune 500 companies, large corporations, and emerging pharmaceutical companies through all stages of trial preparation for patent violation actions, Hudson is an effective advisor through discovery and depositions, claim construction, summary judgment motions, and pretrial and trial proceedings before judges and juries in various federal district courts. She has represented clients in multipatent and multidefendant cases across international borders involving several countries. In addition, she has managed worldwide trademark portfolios and directed trademark and trade dress litigations.
“BakerHostetler knows that pharmaceutical clients require highly skilled practitioners like Ben, Wanda, and now Irene – attorneys who understand the law and its intersection within specific technologies, as well as the industry trends occurring in a changing global marketplace,” said David Sheehan, Intellectual Property Coordinator for the New York office. “Irene is versed in all facets of specialized litigation as it relates to biologics, pharmaceuticals and medical devices and will round out this immensely talented team.”
“We’re thrilled that Irene is joining us in the New York office,” said George Stamboulidis, Managing Partner of BakerHostetler’s New York office. “Her skills enhance a robust team of attorneys focused on ANDA litigation and other IP-related matters across the country.”
“BakerHostetler has a deep bench of intellectual property attorneys who practice across a multitude of life sciences disciplines,” said Hudson. “These synergies generated from the group’s broad industry reach align perfectly with the needs of my clients.”
Hudson is a frequent speaker and presenter on patent litigation, licensing and litigation. She received her J.D. from Hofstra University School of Law in 2002, and earned her B.S. in pharmacy from St. John’s University in 1999.
Biologics and pharmaceutical litigator Irene Hudson strengthens IP Group
BakerHostetler today announced that biologics and pharmaceutical litigator Irene Hudson has joined the Intellectual Property Group and the Biotechnology, Chemical and Pharmaceutical team, resident in the New York office as partner. Hudson comes to BakerHostetler from Fish & Richardson.
Hudson will concentrate her practice on representing domestic and international biologics, pharmaceutical and medical device companies on complex patent infringement litigation, with a particular focus on Hatch-Waxman-based litigation. With a background in pharmacy, Hudson draws on her knowledge of the Food and Drug Administration’s (FDA’s) regulations and statutes concerning New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), Biologics License Applications (BLAs), new drug product exclusivity, and the Hatch-Waxman and Biologics Price Competition and Innovation Act to devise strategies to guide clients through exclusivity rights and challenges involving litigation, arbitration, or mediation.
As part of BakerHostetler’s ongoing strategic expansion in this practice area, Hudson joins other recent additions, Partner Ben Hsing and Counsel Wanda French-Brown. With one of the nation’s largest IP practices, the firm has more than 170 dedicated IP lawyers, with over 100 lawyers and patent agents registered to practice before the U.S. Patent and Trademark Office. “Over the past year, BakerHostetler has focused on building a comprehensive ANDA practice to service our growing roster of clients in the pharmaceutical industry,” said John Weber, Chair of the Intellectual Property Group. “Irene’s extensive experience, particularly working with pharmaceutical and medical device companies, continues to enhance the firm’s specialized skills in this practice area.”
Representing Fortune 500 companies, large corporations, and emerging pharmaceutical companies through all stages of trial preparation for patent violation actions, Hudson is an effective advisor through discovery and depositions, claim construction, summary judgment motions, and pretrial and trial proceedings before judges and juries in various federal district courts. She has represented clients in multipatent and multidefendant cases across international borders involving several countries. In addition, she has managed worldwide trademark portfolios and directed trademark and trade dress litigations.
“BakerHostetler knows that pharmaceutical clients require highly skilled practitioners like Ben, Wanda, and now Irene – attorneys who understand the law and its intersection within specific technologies, as well as the industry trends occurring in a changing global marketplace,” said David Sheehan, Intellectual Property Coordinator for the New York office. “Irene is versed in all facets of specialized litigation as it relates to biologics, pharmaceuticals and medical devices and will round out this immensely talented team.”
“We’re thrilled that Irene is joining us in the New York office,” said George Stamboulidis, Managing Partner of BakerHostetler’s New York office. “Her skills enhance a robust team of attorneys focused on ANDA litigation and other IP-related matters across the country.”
“BakerHostetler has a deep bench of intellectual property attorneys who practice across a multitude of life sciences disciplines,” said Hudson. “These synergies generated from the group’s broad industry reach align perfectly with the needs of my clients.”
Hudson is a frequent speaker and presenter on patent litigation, licensing and litigation. She received her J.D. from Hofstra University School of Law in 2002, and earned her B.S. in pharmacy from St. John’s University in 1999.
Explore more articles in the Top Stories category
